Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    680 result(s) found for: Cellular. Displaying page 3 of 34.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-000228-33 Sponsor Protocol Number: CE/17-12-06 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Saint-Pierre
    Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
    Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003303-14 Sponsor Protocol Number: DETACT Start Date*: 2023-02-16
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT)
    Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001172-41 Sponsor Protocol Number: ITI-007-503 Start Date*: 2022-01-13
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BG (Completed) PL (Completed) SE (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000753-22 Sponsor Protocol Number: TV2/003/06 Start Date*: 2006-05-04
    Sponsor Name:Oxford MioMedica UK Ltd.
    Full Title: A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.
    Medical condition: Advanced or Metastatic Renal Cell Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002589-38 Sponsor Protocol Number: HBV-2013 Start Date*: 2013-07-11
    Sponsor Name:Universität Innsbruck, Institut für Biomedizinische Alternsforschung
    Full Title: Primary and booster vaccination in old age: Hepatitis A and Hepatitis B
    Medical condition: This study will analyze cellular and humoral immune reponses after primary or booster vaccination against HAV and HBV. Healthy adults will be vaccinated with a combination vaccine, which is license...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10054181 Hepatitis B immunization LLT
    16.1 100000004865 10063436 Hepatitis A immunization LLT
    16.1 100000004865 10068384 Hepatitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002147-10 Sponsor Protocol Number: FLU-MARK Start Date*: 2011-09-21
    Sponsor Name:Institute for Biomedical Aging Research
    Full Title: Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders
    Medical condition: This study will analyze cellular and humoral immune responses after seasonal vaccination against influenza. Healthy adults are vaccinated with a licensed trivalent inactivated vaccine without adjuv...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10016794 Flu vaccination LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023230-22 Sponsor Protocol Number: 2010/VCC/0049 Start Date*: 2011-04-12
    Sponsor Name:Velindre NHS Trust
    Full Title: A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma.
    Medical condition: The study is for patients with malignant mesothelioma of the lung lining(called pleura).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000291-11 Sponsor Protocol Number: IMRES Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19)
    Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003632-71 Sponsor Protocol Number: DEND/TIA Start Date*: 2014-07-14
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Dendritic cell-based immunotherapy for advanced solid tumours of children and young adults
    Medical condition: Children and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000982-19 Sponsor Protocol Number: IOBA-ImmunEyez_011-2018 Start Date*: 2019-12-11
    Sponsor Name:Instituto de Oftalmobiología Aplicada (IOBA)
    Full Title: A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved de...
    Medical condition: Dry eye disease with severe keratitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002097-13 Sponsor Protocol Number: SI-05-RG-45 Start Date*: 2017-05-15
    Sponsor Name:Department of Cardiology, University Medical Centre Ljubljana
    Full Title: Comparison of modified-release and standard tacrolimus immunosuppression regimens in heart transplant recipients
    Medical condition: Tacrolimus is a potent immunosuppressant agent widely used for the prevention and treatment of rejection in heart transplant recipients. While tacrolimus is typically administered in two divided do...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005194-77 Sponsor Protocol Number: Matimmunestudyversion2 Start Date*: 2021-10-26
    Sponsor Name:University of Antwerp
    Full Title: The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women
    Medical condition: humoral and cellular immune responses to pertussis vaccine during pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001413-34 Sponsor Protocol Number: VIHCREC01 Start Date*: 2005-04-21
    Sponsor Name:Bonaventura Clotet Sala
    Full Title: ESTUDIO DE UNA DOBLE ESTRATEGIA PARA INDUCIR Y EXPANDIR EL REPERTORIO DE CÉLULAS T BASADA EN LA ADMINISTRACIÓN DE HORMONA DE CRECIMIENTO Y VACUNA EN PACIENTES CON INFECCIÓN POR EL VIH 1
    Medical condition: HIV-1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002378-37 Sponsor Protocol Number: LIS/IMM138 Start Date*: 2008-12-23
    Sponsor Name:National Institute of Health and the Environment (RIVM)
    Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination.
    Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002520-16 Sponsor Protocol Number: 626 Start Date*: 2007-07-06
    Sponsor Name:Universitätsklinik für klinische Pharmakologie, Medizinische Universität Wien
    Full Title: The effects of post-conditioning and administration of Vitamin C on intramuscular high energy phosphate levels
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023034 Ischemia peripheral LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001357-31 Sponsor Protocol Number: IIV-478 Start Date*: 2021-05-03
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002531-56 Sponsor Protocol Number: COVICO Start Date*: 2022-12-28
    Sponsor Name:Sciensano
    Full Title: LONGITUDINAL FOLLOW-UP OF SARS-COV-2 (COVID-19) IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026
    Medical condition: Healthy persons and immunocompromised patients (nursing home residents, dialysis patients and kidney- and lung transplant patients) from age 18 till age 105
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005019-15 Sponsor Protocol Number: CCTL019C2202 Start Date*: 2018-11-08
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N...
    Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002233-11 Sponsor Protocol Number: ELISPOT-TC Start Date*: 2020-01-16
    Sponsor Name:Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge
    Full Title: The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection...
    Medical condition: We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058666 Cytomegalovirus infection reactivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018085-35 Sponsor Protocol Number: 4682724 Start Date*: 2010-05-21
    Sponsor Name:Regionalhospital Silkeborg
    Full Title: Intestinal Inflammation in Ankylosing Spondylitis assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the effects of Adalimumab on mucosal healing
    Medical condition: Ankylosing spondylitis Inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10061371 Spondylitis PT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10041672 Spondylitis ankylosing LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048398 Spondylitis ankylosing aggravated LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10041671 Spondylitis ankylopoietica LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10041673 Spondylitis NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 05:54:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA